Tissue-engineered devices in cardiovascular surgery.

Manufacturing life-long functional cardiovascular (CV) implants is the ultimate goal for researchers and clinicians in the cardiothoracic field. Tissue engineering (TE) is an opportunity to create ideal prostheses that are vital, growing, adaptive, autologous and functionally optimally performing. Today, initial translation from basic science to first clinical trials has begun. The article depicts the state of the art in TE techniques for CV products and describes milestones in the ongoing development of tissue-engineered myocardial, valvular and vascular devices from an experimental and clinical point of view. Artificial CV implants still reveal remarkable limitations but promising advances regarding optimal structural design, the prevention of intimal hyperplasia and the reduction of antigenicity and thrombogenicity. Where applicable, the implantation of vascularized autografts should still be preferred. Apart from that, decellularized allogen bioprostheses currently represent most promising matrix scaffolds that can be autologously cellularized in vitro prior to or in vivo after implantation. Capable biologic alternatives have been described like the decellularized porcine small intestinal submucosa. Rising evidence suggests that in vitro endothelialization might be the minimal requirement for improved long-term results of biological tissue-engineered CV grafts.